A Beta-only IL-2 ImmunoTherapY Study
A phase 1/2 trial of Pembrolizumab in renal cell carcinoma and non-small-cell lung cancer, run by Medicenna Therapeutics, Inc., now recruiting.
Overview
A Beta-only IL-2 ImmunoTherapY Study is a phase 1/2 interventional study registered as NCT05086692 by Medicenna Therapeutics, Inc., with 115 participants planned, started 2021-08-27 and due to reach its primary completion in 2026-06-30. Interventions recorded: MDNA11, Pembrolizumab (KEYTRUDA®). Conditions listed: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of NDI 1150-101 in Patients With Solid Tumors
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialGM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Shares Renal cell carcinoma, Cervical cancer, Pembrolizumab, Colorectal cancer.
- TrialA Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialSafety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Colorectal cancer.
- TrialA Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Shares Renal cell carcinoma, Colorectal cancer, Non-small-cell lung cancer.
- TrialPh I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Shares Renal cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.